亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis

医学 美罗华 胃肠病学 内科学 血管炎 硫唑嘌呤 随机对照试验 冷球蛋白血症 环磷酰胺 血浆置换术 耐火材料(行星科学) 外科 免疫学 化疗 丙型肝炎病毒 淋巴瘤 抗体 病毒 疾病 物理 天体生物学
作者
Salvatore De Vita,Luca Quartuccio,Miriam Isola,Cesare Mazzaro,Patrizia Scaini,Marco Lenzi,M. Campanini,Caterina Naclerio,Antonio Tavoni,Maurizio Pietrogrande,Clodoveo Ferri,Maria Teresa Mascia,Paola Masolini,Alen Zabotti,M. Maset,Dario Roccatello,Anna Linda Zignego,Pietro Pioltelli,Armando Gabrielli,Davide Filippini
出处
期刊:Arthritis & Rheumatism [Wiley]
卷期号:64 (3): 843-853 被引量:392
标识
DOI:10.1002/art.34331
摘要

Abstract Objective To conduct a long‐term, prospective, randomized controlled trial evaluating rituximab (RTX) therapy for severe mixed cryoglobulinemia or cryoglobulinemic vasculitis (CV). Methods Fifty‐nine patients with CV and related skin ulcers, active glomerulonephritis, or refractory peripheral neuropathy were enrolled. In CV patients who also had hepatitis C virus (HCV) infection, treatment of the HCV infection with antiviral agents had previously failed or was not indicated. Patients were randomized to the non‐RTX group (to receive conventional treatment, consisting of 1 of the following 3: glucocorticoids; azathioprine or cyclophosphamide; or plasmapheresis) or the RTX group (to receive 2 infusions of 1 gm each, with a lowering of the glucocorticoid dosage when possible, and with a second course of RTX at relapse). Patients in the non‐RTX group who did not respond to treatment could be switched to the RTX group. Study duration was 24 months. Results Survival of treatment at 12 months (i.e., the proportion of patients who continued taking their initial therapy), the primary end point, was statistically higher in the RTX group (64.3% versus 3.5% [ P < 0.0001]), as well as at 3 months (92.9% versus 13.8% [ P < 0.0001]), 6 months (71.4% versus 3.5% [ P < 0.0001]), and 24 months (60.7% versus 3.5% [ P < 0.0001]). The Birmingham Vasculitis Activity Score decreased only after treatment with RTX (from a mean ± SD of 11.9 ± 5.4 at baseline to 7.1 ± 5.7 at month 2; P < 0.001) up to month 24 (4.4 ± 4.6; P < 0.0001). RTX appeared to be superior therapy for all 3 target organ manifestations, and it was as effective as conventional therapy. The median duration of response to RTX was 18 months. Overall, RTX treatment was well tolerated. Conclusion RTX monotherapy represents a very good option for severe CV and can be maintained over the long term in most patients.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
科研通AI65的应助被晚风采纳,获得10
1秒前
7秒前
8秒前
leo发布了新的文献求助10
12秒前
25秒前
风一样的风干肠完成签到 ,获得积分10
26秒前
30秒前
yqt完成签到,获得积分10
32秒前
32秒前
32秒前
33秒前
fantasy的应助被科研通管家采纳,获得10
33秒前
33秒前
33秒前
晚风发布了新的文献求助10
37秒前
41秒前
xin完成签到,获得积分10
45秒前
Owen的应助被leo采纳,获得10
46秒前
你奶奶完成签到,获得积分10
48秒前
丘比特的应助被你奶奶采纳,获得10
53秒前
Owen的应助被诚心的茉莉采纳,获得10
53秒前
orixero的应助被白华苍松采纳,获得10
58秒前
59秒前
仁爱的鹤轩完成签到,获得积分10
1分钟前
leo发布了新的文献求助10
1分钟前
小王快毕业完成签到,获得积分20
1分钟前
CodeCraft的应助被leo采纳,获得10
1分钟前
晚风发布了新的文献求助10
1分钟前
JY发布了新的文献求助10
1分钟前
1分钟前
今后的应助被林林采纳,获得10
1分钟前
机灵的以莲完成签到,获得积分10
1分钟前
yc发布了新的文献求助10
1分钟前
1分钟前
leo发布了新的文献求助10
1分钟前
wanci的应助被leo采纳,获得10
1分钟前
半山听雨N完成签到 ,获得积分10
1分钟前
LL发布了新的文献求助10
2分钟前
在水一方的应助被deng20065采纳,获得10
2分钟前
我是老大的应助被wuyp采纳,获得10
2分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8190078
求助须知:如何正确求助?哪些是违规求助? 9577216
关于积分的说明 21852047
捐赠科研通 7788239
什么是DOI,文献DOI怎么找? 3436240
关于科研通互助平台的介绍 2559964
邀请新用户注册赠送积分活动 2482824